Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer

Smith Giri1,2,* , Nabil Mir3,*, Mustafa Al-Obaidi1, Deanna Clark1, Kelly M. Kenzik1,2, Andrew McDonald1, Crystal Young-Smith2, Ravi Paluri2, Lakshmin Nandagopal2, Olumide Gbolahan2, Kirsten A. Nyrop4, Hyman B. Muss4, Mackenzi Pergolotti5,6, Smita Bhatia1, Grant R. Williams1,2

1Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, AL, USA
2Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
3Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
4Division of Oncology, The University of North Carolina at Chapel Hill, NC, USA
5Revital Cancer Rehabilitation, Select Medical, Mechanicsburg, PA, USA
6Department of Occupational Therapy, Colorado State University, Fort Collins, CO, USA

*Corresponding author: Smith Giri, Division of Hematology/Oncology, Institute of Cancer Outcomes and Survivorship, University of Alabama at Birmingham, 600 7th Avenue South, Lowder 500, Birmingham, AL 35233, USA. Tel: +1 205 638 7000; Fax: +1 205 638 2121; Email: smithgiri@uabmc.edu

Abstract

Background: Poor self-rated health (SRH) is a known predictor of frailty and mortality in the general population; however, its role among older adults with cancer is unknown. We evaluated the role of SRH as a potential screening tool to identify frailty and geriatric assessment (GA)-identified impairments.

Materials and Methods: Adults ≥60 years diagnosed with cancer in the UAB Cancer & Aging Resilience Evaluation (CARE) registry underwent a GA at the time of initial consultation. We measured SRH using a single-item from the Patient-Reported Outcomes Measurement Information System global health scale and dichotomized responses as poor (poor, fair) and good (good, very good, and excellent). We evaluated the diagnostic performance of SRH in measuring frailty, and GA impairment (≥2 deficits among a set of seven GA domains). We examined the impact of SRH with survival using a Cox model adjusting for confounders, exploring the mediating role of frailty.

Results: Six hundred and three older adults with cancer were included, with a median age of 69 years. Overall, 45% (n = 274) reported poor SRH. Poor SRH demonstrated high sensitivity and specificity for identifying frailty (85% and 78%, respectively) and GA impairment (75% and 78%, respectively). In a Cox regression model, poor SRH was associated with inferior survival (HR = 2.26; 95% CI 1.60-3.18) after adjusting for confounders; frailty mediated 69% of this observed relationship.

Conclusion: Self-rated health may be used as a screening tool to identify older adults with cancer with frailty and GA impairments. Poor SRH is associated with inferior survival, which is mediated by frailty.

Key words: self-rated health; frailty; geriatric assessment; geriatric oncology; aging

Implications for Practice

In this prospective cohort study involving 603 older adults ≥60 years with cancer, poor self-rated health at the time of initial consultation with a medical oncologist demonstrated a high sensitivity and specificity for frailty (85% and 78%, respectively) and GA impairment (75% and 78%, respectively), which was independently confirmed in an external replication cohort. Poor SRH was associated with inferior survival after adjusting for age, sex, race, cancer type/stage, and planned therapy. A single item question on self-rated health may be used to screen older adults with cancer who are likely to have frailty and geriatric assessment identified impairments.

Introduction

More than 60% of new cancer diagnoses occur among adults aged 65 years or older.1 Although, older adults with cancer are at high risk of treatment-related toxicity and inferior survival, chronologic age by itself does not adequately explain inter-individual variability in outcomes.2 A geriatric assessment (GA) can identify vulnerable or “frail” older adults at greatest risk for treatment-related adverse events3–8, health care utilization,9 and mortality. Currently, the American Society of Clinical Oncology10 and the National Comprehensive Cancer Network (NCCN)11 recommend using GA to personalize and guide clinical care in older adults. Yet, widespread use of GA

Received 29 December 2020; Accepted 16 September 2021.
© The Author(s) 2022. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
in oncology practice remains limited due to perceived complexity as well as time/resource constraints. While there are few screening tools to identify patients at greatest risk of GA impairments, a primarily self-administered single-item screening tool represents an unmet need.

Self-rated health (SRH) is a widely used measure of health, where patients are asked to report their health status based on their own definition of health. It is typically measured using a single item question, commonly worded as “In general would you say your health is” with the response items “excellent”, “very good”, “good”, “fair” or “poor”. While, SRH captures an individual’s perception of their overall health, it has been shown to correlate well with performance-based measures of health. Among community-dwelling older adults, SRH predicts functional limitation, cognitive impairment, health care utilization, and survival. Yet, there is limited data regarding the utility of this tool to predict adverse outcomes among older patients with cancer.

Here, we evaluated SRH as a screening tool to identify older adults with cancer at risk of frailty and GA-identified impairments and its association with mortality.

**Methods**

**Study Population**

We used participants from the University of Alabama at Birmingham (UAB) Cancer and Aging Resilience Evaluation (CARE) study—a prospective registry enrolling older adults (≥60 years) undergoing cancer treatment at UAB Hospitals and Clinics. We chose 60 years of age as criteria for enrollment in this registry given recognition of the uncertainty of the “right” age cutoff and to allow for meaningful age-related sub-analyses such as the current study. For the current report, we included patients completing GA at the time of initial consultation to the UAB medical oncology clinic between 9/2017 and 10/2019. The Institutional Review Board of UAB (IRB-300000092) approved this study.

**Self-Rated Health**

We measured SRH using a single-item question from the Patient-Reported Outcomes Measurement Information System (PROMIS) global health scale, incorporated as a part of the GA. The question is worded as: “In general, would you say your health is?” with the following possible responses scaled on a 5-point Likert scale, “excellent”, “very good”, “good”, “fair”, or “poor”. We then dichotomized these responses to poor (poor, fair) and good (very good, good, excellent), consistent with other studies.

**Baseline Geriatric Assessment**

All participants completed patient-reported GA as previously published (Supplementary Table S1). Briefly, CARE GA is a modified version of the Cancer and Aging Research Group GA and includes the following domains: functional status, comorbidity, cognition, mood disorders, nutrition, social support, and HRQoL, consistent with recommendations from the International Society of Geriatric Oncology.

**Frailty Index**

We constructed a frailty index using the principle of deficit accumulation approach originally described by Rockwood et al and following the standard procedures outlined by Searle et al. We used 44 GA variables from the CARE survey (Supplementary), and categorized patients as robust (0-0.2), pre-frail (0.2-0.35), and frail (>0.35), as previously described. An index constructed with ≥30 items has been previously shown to predict adverse outcomes and survival among older adults.

**GA Impairment**

We classified patients as having significant GA impairment if they had ≥2 impairments among the following seven domains: impairment in any activities of daily living (ADL); impairments in ≥2 instrumental activities of daily living (IADL); limitation in walking one block; significant weight loss (3% in 3 months or 6% in 6 months); presence of ≥4 comorbidities; presence of depression (T-score ≥60) and cognitive impairment (T-score ≤40) (Supplementary). Additionally, we conducted a sensitivity analysis varying our definition of GA impairment as ≥1 GA impairment as well as ≥3 GA impairments.

**Additional Variables**

Information on vital status was updated to January 12, 2019, linking the study cohort to Accurint database, which uses death information from Social Security Administration records, obituaries and state death records, and supplemented by review of medical records. We abstracted information on demographic and clinical characteristics including age at the time of GA evaluation, sex, race/ethnicity, cancer type, cancer stage, and planned systemic therapy from medical records.

**External Validation**

We obtained data on 372 older adults ≥60 years with cancer enrolled in the Carolina Senior Registry (n = 208) and four exercise intervention trials (n = 164; NCT011789983, NCT02167932, NCT02328313, and NCT037611706) at the University of North Carolina at Chapel Hill. We measured and similarly categorized SRH based on a single-item question from the PROMIS global health scale. Frailty was defined using the 36-item Carolina Frailty Index as previously reported. Meanwhile, GA impairment was defined as the presence of ≥2 impairments among the following seven domains: impairments in ≥2 IADL; abnormal timed get up and go test (≥20 s); limitation in walking one block; significant weight loss (5% within 6 months); presence of ≥4 comorbidities using OARS comorbidity assessment; presence of depression (13-item Mental Health Index score ≥12); and cognitive impairment ( Blessed Orientation Memory Concentration test score ≥11). Of note, data on ADL were not available and abnormal TUG ≥20 s was used as a surrogate for ADL, as shown before.

**Statistical Analyses**

We compared the baseline demographic, clinical and GA characteristics between patients reporting poor and good SRH by using distribution appropriate statistical tests. We examined the diagnostic performance of SRH for measuring frailty (frail vs others) and GA impairment in terms of sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve (ROC AUC). We computed binomial exact 95% confidence intervals for sensitivity, specificity, positive predictive value, and negative predictive value. Meanwhile, the AUC and its asymptotic normal 95%
Most patients responded to the single item SRH question as good (33.7%; n = 203) or fair (31.5%; n = 190) (Supplementary Figure S2). Upon dichotomizing the responses as poor (poor and fair) or good (very good, and excellent), poor SRH was reported by 45% of participants (n = 274). When compared with patients with good SRH, those reporting poor SRH were more likely to be female (66% vs 57%; P = .02), have less than high school education (19% vs 13%, P < .001), diagnosis of pancreatic cancer (21% vs 14%; P = .04), and stage IV disease (56% vs 45%; P = .01) (Table 1).

Association of SRH with Frailty and Geriatric Impairment

The prevalence of frailty was significantly higher among patients with poor SRH when compared with those reporting good SRH (68% vs 10%; P < .001). Similarly, patients with poor SRH were more likely to have GA impairment (≥2 GA domain impairments) When compared with those with good SRH (74% vs 21%, P < .001) as well as domain-specific impairments in ADL, IADL, depression anxiety, multimorbidity, polypharmacy, malnutrition, and one or more falls (Figure 1).

Diagnostic Validity of SRH as a Screening Tool for Frailty and GA Impairments

We first confirmed that our binary classification of SRH, ie, good (very good, and excellent) versus poor (poor or fair) was also the optimal cut point offering the best balance between sensitivity and specificity (Figure 1). Using this cut point, SRH demonstrated high sensitivity (85%) and specificity (78%) for identifying frail patients, with a positive predictive value (PPV) of 69% and negative predictive value (NPV) of 90%. Similarly, the sensitivity and specificity of SRH in identifying patients with GA impairment (>2 GA domain impairments) was 75% and 78%, respectively, with a PPV of 74% and NPV of 79% (Table 2). Finally, in a preplanned sensitivity analysis, the sensitivity/specificity of SRH in identifying patients with ≥1 GA domain impairment and ≥3 main impairments) was 75% and 78%, respectively, with a PPV of 69% vs 21% (P < .001) (Table 2). Similarly, consistent results were obtained when limiting our cohort to age ≥70 years (Supplementary Table S2).

Association of SRH with Mortality

When compared with patients with good SRH, those reporting poor SRH had a significantly worse survival (1-year OS 62.4% vs 82.6%, log-rank P < .001; Figure 2). In a multivariable Cox regression analysis, poor SRH remained an independent predictor of worse survival (hazard ratio [HR] 2.26 [1.60-3.18], P < .001) after adjusting for age, sex, race, cancer type, and planned chemotherapy as well as accounting for cancer stage as stratification variable (Table 3).

Association of Frailty with Mortality

We confirmed that the CARE-Frailty Index provided stratification of survival, discerning groups with 1-year overall survival ranging between 85.7% for robust, 76.5% for prefrail, and 58.5% for frail patients, respectively (log-rank test for trend P < .001) (Supplementary Figure S2). Furthermore, in a multivariable Cox regression model, frail patients had a worse overall survival when compared to non-frail patients (HR 2.25 [1.27-3.98], P < .001) after adjusting for age, sex, race, cancer type, cancer stage, SRH, and planned chemotherapy as well as accounting for cancer stage as stratification variable (Table 3).

Results

Of the 708 older adults diagnosed with cancer in the CAREregistry, 603 (85%) underwent GA and reported on SRH at the time of initial consultation with a medical oncologist (Supplementary Figure S1). The median time from diagnosis to GA was 37 days (IQR 19-112 days). The median age at study enrollment was 69y (IQR 64-274 years), with 61% females and 75% whites. Common cancers included colorectal cancer (24%), pancreatic cancer (17%), and hepatobiliary cancers (13%). Almost half of the participants presented with stage IV disease (Table 1).

confidence interval was calculated using the non-parametric method proposed by DeLong et al. We identified the optimal cut point for dichotomizing original SRH responses using the method proposed by Liu, aiming to maximize the product of sensitivity and specificity. Additionally, we reported the above diagnostic performance, by varying our definitions of GA impairment as presence of ≥1, or ≥3 GA domain impairments, as well by restricting to those age ≥70 years. We then independently confirmed our findings in the replication cohort.

The median follow-up of the study cohort was estimated using reverse Kaplan–Meier method. To account for variation in time between the date of diagnosis and time of GA evaluation, we used a landmark analysis using the date of GA evaluation as the start of follow-up. We used Kaplan–Meier methods and log-rank test to compare the survival distributions between those reporting good vs poor SRH. We used Cox proportional hazards regression to evaluate the independent impact of SRH on overall survival adjusting for potential confounders including age, sex, race, cancer type/stage, and planned systemic therapy. We tested proportionality assumption of the Cox model using Schoenfeld residuals and testing for interaction using log person-time; covariates violating this assumption were used as stratification variables in the final model.

Finally, we hypothesized that frailty might act as a mediator between SRH and survival. Conceptually, a mediation analysis attempts to break down the total effect of an exposure (SRH) on outcome (overall survival) into two parts: (1) direct effect: effect of an exposure on an outcome in the absence of mediators and (2) indirect effect: effect of an exposure on outcome explained by a set of mediator (Frailty). To allow for interaction between SRH and frailty, we used the four-way decomposition as proposed by Vanderweele to conduct this mediation analysis. This method breaks down the overall effect (the total effect) of an exposure (self-rated health) on outcome (overall survival), in the presence of a mediator (frailty) into four components; (1) the effect of exposure in the absence of the mediator; (2) effect due to interaction only, (3) effect due mediation and interaction, and (4) due to mediation only. We estimated mediation with “exposure” defined as a dichotomized measure of self-reported health (poor/fair vs. good/excellent) and the mediator focused on frailty index as a continuous variable. We specified an accelerated failure time model with Weibull distribution and used the Med4way package in STATA to estimate the causal contrasts that arise in the above decomposition.

All hypothesis testing was two-sided, and the level of the significance was set at .05. We conducted statistical analysis using SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC) and STATA v13.0 (StataCorp LLC, College Station, TX).
chemotherapy. Interestingly, the prognostic impact of SRH remained no longer significant (HR 1.44 [0.91-2.29], P = .12) after adding frailty into the multivariable analysis, suggesting a possible mediating role (Supplementary Table S3).

### Mediation Analyses

We conducted a four-way decomposition analysis to identify the proportion of the observed relationship between SRH and mortality (ie, total effect) that is mediated by frailty. The

### Table 1. Comparison of baseline demographic and clinical characteristics among patients reporting poor and good self-rated health.

| Variable                                      | Poor SRH | Good SRH | P-value |
|-----------------------------------------------|----------|----------|---------|
| N                                             | 274      | 329      |         |
| Demographic characteristics                   |          |          |         |
| Age in years, median (IQR)                    | 68 (63-74) | 69 (64-75) | .02 |
| Age category, n (%)                           |          |          | .13    |
| 60-69 years                                   | 162 (59.1%) | 165 (50.2%) | |
| 70-79 years                                   | 84 (30.7%) | 129 (39.2%) | |
| 80-89 years                                   | 26 (9.5%) | 33 (10%) | |
| 90+                                           | 2 (0.7%) | 2 (0.6%) | |
| Sex, n (%)                                    |          |          | .02    |
| Male                                          | 94 (34.3%) | 143 (43.5%) | |
| Female                                        | 180 (65.7%) | 186 (56.5%) | |
| Race, n (%)                                   |          |          | .09    |
| White                                         | 195 (71.2%) | 254 (77.2%) | |
| Black                                         | 76 (27.7%) | 68 (20.7%) | |
| Other                                         | 3 (1.1%) | 7 (2.1%) | |
| Marital status, n (%)                         |          |          | .19    |
| Single                                        | 23 (8.4%) | 17 (5.2%) | |
| Widowed/divorced/separated                    | 73 (26.6%) | 86 (26.1%) | |
| Married                                       | 165 (60.2%) | 217 (66.0%) | |
| Unknown                                       | 13 (4.7%) | 9 (2.7%) | |
| Education, n (%)                              |          |          | <.001  |
| Less than high school                         | 53 (19.3%) | 41 (12.5%) | |
| High school graduate                         | 82 (29.9%) | 69 (21.0%) | |
| Associate/bachelors                           | 106 (38.7%) | 173 (52.6%) | |
| Advanced degree                               | 15 (5.5%) | 41 (12.5%) | |
| Unknown                                       | 18 (6.6%) | 5 (1.5%) | |
| Clinical characteristics                      |          |          | .95    |
| Time from diagnosis, median (IQR) days        | 38 (19, 120) | 37 (18, 112) | |
| Cancer type, n (%)                            |          |          | .04    |
| Colorectal                                    | 54 (19.7%) | 93 (28.3%) | |
| Pancreatic                                    | 58 (21.2%) | 46 (14.0%) | |
| Hepatobiliary                                 | 33 (12.0%) | 45 (13.7%) | |
| Gastroesophageal                              | 25 (9.1%) | 21 (6.4%) | |
| Neuroendocrine carcinoma                      | 19 (6.9%) | 19 (5.8%) | |
| Prostate cancer                               | 17 (6.2%) | 26 (7.9%) | |
| Lung cancer                                   | 22 (8.0%) | 14 (4.3%) | |
| Head and neck cancer                          | 12 (4.4%) | 20 (6.1%) | |
| Other                                         | 34 (12.4%) | 45 (13.7%) | |
| Cancer stage, n (%)                           |          |          | .03    |
| Stages I-II                                   | 65 (23.7%) | 85 (25.8%) | |
| Stage III                                     | 52 (36.1%) | 92 (28.0%) | |
| Stage IV                                      | 151 (50.7%) | 147 (44.7%) | |
| Unknown                                       | 6 (54.6%) | 5 (45.5%) | |
| Planned chemotherapy, n (%)                   |          |          | .02    |
| No                                            | 71 (25.9%) | 60 (18.2%) | |
| Yes                                           | 203 (74.1%) | 269 (81.8%) | |

Abbreviations: SRH, self-rated health; IQR, inter-quartile range; CARE, Cancer and Aging Resilience Evaluation.
The Oncologist, 2022, Vol. XX, No. XX

The details of the mediation analysis are presented in supplementary files (Supplementary S1; Table S4), where the effect sizes of each component are represented in the ratio scale and the total and the total excess risk is broken down into four parts: (1) excess relative risk due to controlled direct effect (effect of SRH on survival without mediation or interaction), (2) excess relative risk due to reference interaction (interaction only), (3) excess relative risk due to mediated interaction (due to both interaction and mediation), and (4) excess relative risk due to pure indirect effect (due to mediation only). Based on our four-way decomposition analysis, we found that frailty as a mediator explained 69% of the observed impact of SRH on survival, whereas the direct effect and interaction terms were not significant (Supplementary Table S4).

External Validation

Our replication cohort comprised of 372 older adults ≥60 years with cancer, with a median age of 73 years (range 60-91 years), 47% females, 86% non-Hispanic white and with multiple myeloma (18%), breast cancer (17%), and prostate cancer (13%) being most common diagnoses. In this cohort, the prevalence of frailty was 17%, whereas 26% had significant GA impairment (≥2 GA domain impairments). Self-rated health demonstrated moderate sensitivity (61%) and high specificity (87%) for capturing frailty, as well as GA impairment (61% sensitivity, 87% specificity) (Table 2).
Table 3. Multivariable Cox proportional hazards regression model showing association between self-rated health and overall survival.*

| Variable                | Hazard ratio | 95% CI     | P-value |
|-------------------------|--------------|------------|---------|
| Self-rated health       |              |            | <.001   |
| Good                    | Ref          | —          |         |
| Poor                    | 2.26         | 1.60-3.18  | .001    |
| Age in years (continuous) | 0.99        | 0.98-1.02  | .99     |
| Sex                     |              |            | .78     |
| Female                  | Ref          | —          |         |
| Male                    | 1.05         | 0.74-1.48  |         |
| Race                    |              |            |         |
| White                   | Ref          | —          |         |
| Black                   | 0.83         | 0.56-1.24  | .36     |
| Other                   | 2.48         | 0.75-8.16  | .14     |
| Planned chemotherapy    | 0.90         | 0.60-1.34  | .61     |
| Cancer stage            |              |            |         |
| Stages I–II             | Ref          | —          |         |
| Stage III               | 0.81         | 0.47-1.41  | .46     |
| Stage IV                | 2.43         | 1.61-3.69  | <.001   |

*Cancer type was treated as a stratification variable in the survival analysis. Index date for survival analysis is the date of CARE survey including SRH assessment.

Discussion

In this study of 975 older adults with cancer, we found that a single-item SRH question has a moderate-to-high sensitivity and a high specificity for capturing frailty and GA impairment, suggesting its value as a simple, one-item screening tool for identifying vulnerable older adults with cancer who require further evaluation with a GA. Furthermore, we demonstrated that poor SRH is independently associated with inferior survival, and this effect is largely mediated by a higher prevalence of frailty in this population.

Despite overwhelming evidence regarding the role of GA in capturing frailty and GA impairments among older adults with cancer, widespread implementation remains limited due to perceived complexity, interruption in clinic workflow, and time/resource constraints. To our knowledge, this is the first study to demonstrate the utility of single-item SRH question as a potential screening tool for identifying older cancer patients with frailty and GA impairments. Among older adults ≥60 years with chronic kidney disease, single item SRH demonstrated a 70.0% sensitivity and 92.0% NPV in identifying frail individuals using Fried phenotype as well as Dalhousie Clinical Frailty Score. Similar findings were reported in 243 community dwelling older adults aged ≥75 years, where SRH had a sensitivity of 62.5%, specificity of 93.6%, and a PPV/NPV of 67.5%/92.2%. Notably, both studies report a high NPV of this tool (≥90%), arguing that patients reporting excellent, very good or good SRH are very unlikely to have frailty and a comprehensive GA can be likely deferred.

We found that SRH was associated with several domain-specific impairments among older adults with cancer. This is consistent with prior observations that older adults reporting poor SRH have a higher prevalence of ADL impairments, IADL impairments, cognitive impairment, malnutrition, and multimorbidity. Additionally, SRH independently predicted overall survival in our cohort; a finding that has been reported among community dwelling older adults, older adults presenting to the ED, or hospital, and those with chronic kidney disease, coronary artery disease, and cognitive impairment. Only few studies, however, have evaluated the association of SRH with mortality among patients with cancer; among 735 adults with advanced malignancy, SRH predicted survival independent of the individual’s performance status. In another population-based observational study, SRH status predicted non-prostate cancer mortality among men with localized prostate cancer. Furthermore, we show that this association is mediated by frailty, demonstrating the value of SRH in capturing frailty among older adults with cancer.

Recognizing the challenge to identify older adults with cancer for whom a comprehensive GA would be most beneficial, several screening tools have been previously explored. Bellera et al evaluated the G-8 tool, incorporating age and seven items from the Mini Nutritional Assessment and reported a sensitivity of 85% and 92% as well as specificity of 65% and 48% respectively for identifying patients with ≥1 and ≥2 GA impairments, respectively. Similarly, the Flemish version of the Triage Risk Screening Tool (fTRST), a five-item screening tool, had a sensitivity of 67% and specificity of 74% in identifying older adults ≥70 years with cancer who had ≥2 geriatric impairments. Finally, among older adults ≥70 years with prostate cancer, Mohile et al showed that the 13-item Vulnerable Elders Survey (VES-13) had a sensitivity of 73% and specificity of 86% in identifying older adults with ≥2 GA impairments. It is important to note that both G-8 and VES-13 include a self-rated health as a component. However, in contrast to the above screening tools, SRH is a simple, practical, and an easily scalable single-item screening tool. Moreover, we show for the first time that SRH can identify frail older adults with cancer as well.

Our study has limitations. Over 60% of our cohort had gastrointestinal malignancies recruited from a single institution in the southeastern USA. As such, our findings may not be readily applicable to other malignancies or populations. Of note, our replication cohort from a different site with different cancer types had similar results. We cannot rule out the possibility of selection bias, where fit patients with good health may be more likely to complete the CARE survey as opposed to those in poor health. However, over
92% of all newly diagnosed gastrointestinal malignancies presenting to the GI oncology clinic are currently included in the CARE registry.2 We had limited clinical information regarding type and intensity of chemotherapy, tumor grade, lymph node involvement, and tumor markers that may adversely affect survival in our cohort. Our follow-up time was relatively short; additional follow-up with more mature survival data is needed. We were not able to directly compare SRH with established GA screening tools such as G-8,10 fTRST,84 and VES-1365. Finally, due to the self-reported nature of this instrument, SRH may not be useful as a screening tool for older adults with moderate to severe cognitive impairment.

In conclusion, a single-item SRH question is a potential screening tool for capturing frailty and GA impairments among older adults with cancer. Future studies should validate our findings in geographically diverse cohorts across different cancer types and compare it against established screening tools.

Acknowledgments
S.G. and G.R.W. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding
Supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and the National Cancer Institute of the National Institutes of Health (K08CA234225). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Submitted in abstract form to the American Society of Clinical Oncology 2020 Annual Meeting.

Conflict of Interest
Smith Giri: Carevive Systems, Pack Health LLC (RF), Carevive Systems (H); Grant R. Williams: Carevive Systems (C/A). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (H) Honoraria received

Author Contributions
Conception/design: S.G., G.R.W. Provision of study material or patients: S.G., G.R.W. Collection and/or assembly of data: S.G., G.R.W. Data analysis and interpretation: S.G., G.R.W. Manuscript writing: all authors. Final approval of manuscript: all authors.

Data Availability
The data underlying this article will be shared on reasonable request to the corresponding author.

Supplementary material
Supplementary material is available at The Oncologist online.

References
1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
2. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305-e316.
3. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
4. Williams GR, Dunham L, Chang Y, et al. Geriatric assessment predicts hospitalization frequency and long-term care use in older adult cancer survivors. J Oncol Pract. 2019;15(7):1426-1433.
5. Williams GR, Deal AM, Sanoff HK, et al. Frailty and health-related quality of life in older women with breast cancer. Support Care Cancer. 2019;27(7):2693-2698.
6. Guerard EJ, Deal AM, Chang Y, et al. Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer. J Natl Compr Canc Netw. 2017;15(7):894-902.
7. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326-2347.
8. National Comprehensive Cancer Network. Older Adult Oncology (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed March 7, 2020.
9. Korc-Grodzicki B, Holmes HM, Shahrooki A. Geriatric assessment for oncologists. Cancer Biol Med. 2015;12(4):261-274.
10. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166-2172.
11. Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109(4):802-810.
12. Jylhä M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Soc Sci Med. 2009;69(3):307-316.
13. Wu S, Wang R, Zhao Y, et al. The relationship between self-rated health and objective health status: a population-based study. BMC Public Health. 2013;13:320.
14. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. J Gen Intern Med. 2006;21(3):267-275.
15. Ellen L. Idler LBR, Davis D. Survival, functional limitations, and self-rated health in the NHANES I epidemiologic follow-up study, 1992. Am J Epidemiol. 2000;152(9):874-883.
16. Elaine A. Borawski JMK, Kahana E. The meaning of older adults’ health appraisals: congruence with health status and determinant of mortality. J Gerontol Soc Sci. 1996;51B(3):S157-S170.
17. Benjamini Y. Self-ratings of health and longevity: a health psychologist’s viewpoint on epidemiological findings. Eur Health Psychologist. 2008;10(10):10-13.
18. Williams GR, Kenzik KM, Parman M, et al. Integrating geriatric assessment into routine gastrointestinal (GI) consultation: the cancer and aging resilience evaluation (CARE). J Geriatr Oncol. 2020;11(2):270-273.
19. Mir N, MacLennan P, Al-Obaidi M, et al. Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis- Results from the Cancer & Aging Resilience Evaluation (CARE) study. J Geriatr Oncol. 2020;11(6):982-988.
20. Alexio GFP, Choi SK, Tan AJ, et al. Is “Geriatric” assessment just for older patients? Oncologist. 2020;25(4):355-358.
21. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873-880.
22. Greiner PA, Snowdon DA, Greiner LH. Self-rated function, self-rated health, and postmortem evidence of brain infarcts-findings from the Nun Study. J Gerontol B Psychol Sci Soc Sci. 1999;54(4):S219-S222.
43. Pergolotti M, Langer MM, Deal AM, Muss HB, Nyrop K, Williams J. Predicting the probability for falls in community-dwelling older adults using the timed up & go test. Phys Ther. 2000;80(9):896-903.

44. Katzman R, Brown T, Fulfd P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734-739.